Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...

Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect.

TD Cowen analyst Yaron Werber initiated coverage of Forte Biosciences (FBRX) with a Buy rating and no price target The firm says FB102 is a ...

Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients ...

NDAQ:TLSA) Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 ...

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an ag ...

The human immune system is a complex network of cells and signals that guards against disease, yet in the case of cancer, it often struggles to mount an effective response. Recent research, published ...

to investigate whether the generation of inducible Foxp3-expressing regulatory T cells (Treg) might constitute additional mechanisms underlying the immunosuppressive properties of MMF. The animals ...

T-cell lymphoma is a type of lymphatic cancer that starts in the T lymphocytes (T cells), a type of white blood cell. T lymphocytes (T cells) and B lymphocytes (B cells) are two types of white blood ...

On the other hand, Tregs mediate immunological tolerance against self-antigens and harmless foreign antigens such as food and intestinal microbiota. Furthermore, they control the immune response via ...